WallStreetZenWallStreetZen

NASDAQ: SONN
Sonnet Biotherapeutics Holdings Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Sonnet Biotherapeutics Holdings revenue was $1.00M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $1.0M, up Infinity% from last quarter. For the last reported fiscal year 2024 ending Sep 30, 2024, SONN annual revenue was $18.6k, with -87.4% growth year-over-year.

SONN past revenue growth

How has SONN's revenue growth performed historically?

Company
674.14%
Industry
497.69%
Market
20.68%
SONN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
SONN's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
SONN's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

SONN revenue history

Current Revenue
$1.0M
Current Earnings
-$9.4M
Current Profit Margin
-942.9%

Be the first to know when SONN announces revenue.

SONN Revenue History By Year

SONN Yearly RevenueSONN RevenueSONN ChangeSONN Revenue Growth
2024-09-30$18.63k-$129.18k-87.40%
2023-09-30$147.81k-$202.14k-57.76%
2022-09-30$349.94k-$133.68k-27.64%
2021-09-30$483.63kN/AN/A
2020-09-30$0.00N/AN/A
2019-09-30$0.00-$30.73M-100.00%
2018-12-31$30.73M-$10.70M-25.82%
2017-12-31$41.43M-$269.14k-0.65%
2016-12-31$41.70M$6.35M+17.96%
2015-12-31$35.35M$5.51M+18.46%
2014-12-31$29.84M$21.60M+261.85%
2013-12-31$8.25M$1.40M+20.36%
2012-12-31$6.85M$5.38M+364.05%
2011-12-31$1.48M$1.34M+983.37%
2010-12-31$136.30k-$466.68k-77.40%
2009-12-31$602.98k$368.92k+157.62%
2008-12-31$234.06k-$297.19k-55.94%
2007-12-31$531.25k$404.00k+317.51%
2006-12-31$127.24k$122.45k+2,552.00%
2005-12-31$4.80kN/AN/A
2004-12-31$0.00N/AN/A

1 of 2

Sonnet Biotherapeutics Holdings Revenue FAQ

What was SONN's revenue last quarter?

On Invalid Date, Sonnet Biotherapeutics Holdings (NASDAQ: SONN) reported Q4 2024 revenue of $1.00 million up 5,268.84% year over year. In the same quarter last year, Sonnet Biotherapeutics Holdings's revenue was $18.63 thousand.

What was Sonnet Biotherapeutics Holdings's revenue in 2024?

Sonnet Biotherapeutics Holdings's annual revenue for the twelve months ending Sep 30, 2024 was $18.63 thousand, a 87.4% decrease year over year.

How much does Sonnet Biotherapeutics Holdings make in a day?

Based on Sonnet Biotherapeutics Holdings annual revenue for the past five years, SONN makes an average of $547.95 per day.

What was Sonnet Biotherapeutics Holdings's annual revenue growth in the past year?

As of Q2 2025, Sonnet Biotherapeutics Holdings's revenue has grown 674.14% year over year. This is 176.44 percentage points higher than the US Biotechnology industry revenue growth rate of 497.69%. Sonnet Biotherapeutics Holdings's revenue in the past year totaled $1.00 million.

How much does Sonnet Biotherapeutics Holdings make in a year?

Sonnet Biotherapeutics Holdings's revenue by year for the past five years is:
  • Sonnet Biotherapeutics Holdings's revenue for the twelve months ending Sep 30, 2024 was $18.63 thousand, a 87.4% decrease year over year.
  • Sonnet Biotherapeutics Holdings's annual revenue for Sep 30, 2023 was $147.81 thousand, a 57.76% decrease from 2022.
  • Sonnet Biotherapeutics Holdings's annual revenue for 2022 was $349.94 thousand, a 27.64% decrease from 2021.
  • Sonnet Biotherapeutics Holdings's annual revenue for 2021 was $483.63 thousand, a Infinity% increase from 2020.
  • Sonnet Biotherapeutics Holdings's annual revenue for 2020 was $0.00, a N/A decrease from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.